Production and Purification of Recombinant Proteins

  • Alfred Luitjens
  • Emile van CorvenEmail author


The growing demand for therapeutic proteins, especially monoclonal antibodies, increases the need for practical and economical processing techniques. Such techniques evolved rapidly over the last few decades. In this chapter an overview is given of the main biotechnological production systems with a focus on mammalian cultures and a brief description of prokaryotic cell systems, transgenic technology and plant cells, and of the main purification systems with a focus on technologies such as filtration, centrifugation, precipitation and chromatography. The critical quality attribute concept of biopharmaceuticals is discussed and its relation to the concept of quality by design, as well as strategies to decrease the cost of goods and increase process robustness to ensure consistent and safe production of biopharmaceuticals within large scale manufacturing plants.


Recombinant proteins Production Purification Quality Efficiency Downstream processing Upstream processing 


  1. Abi-Ghanem DA, Berghman LR (2012) Immunoaffinity chromatography: a review.
  2. Afeyan N, Gordon N, Mazsaroff I, Varady L, Fulton S, Yang Y, Regnier F (1989) Flow-through particles of the high-performance liquid chromatographic separation of biomolecules, perfusion chromatography. J Chromatogr 519:1–29CrossRefGoogle Scholar
  3. Berridge J, Seamon K, Venugopal S (2009) A-Mab: a case study in BioProcess development, version 2.1, 30th October 2009.
  4. Berthold W, Walter J (1994) Protein purification: aspects of processes for pharmaceutical products. Biologicals 22:135–150CrossRefGoogle Scholar
  5. BioPhorum Operations Group (2017) Biomanufacturing technology roadmap.
  6. Cartwright T (1987) Isolation and purification of products from animal cells. Trends Biotechnol 5:25–30CrossRefGoogle Scholar
  7. Celik E, Calik P (2012) Production of recombinant proteins by yeast cells. Biotechnol Adv 30(5):1108–1118CrossRefGoogle Scholar
  8. Chase H, Draeger N (1993) Affinity purification of proteins using expanded beds. J Chromatogr 597:129–145CrossRefGoogle Scholar
  9. Chase HA (1994) Purification of proteins by adsorption chromatography in expanded beds. Trends Biotechnol 12:296–303CrossRefGoogle Scholar
  10. Chen T, Zhang K, Gruenhagen J, Medley CD (2015) Hydrophobic interaction chromatography for antibody drug conjugate drug distribution analysis. american pharmaceutical review.
  11. Compton B, Jensen J (2007) Use of perfusion technology on the Rise – New modes are beginning to gain ground on Fed-Batch strategy. Genet Eng Biotechnol News 27:48Google Scholar
  12. Council of Europe (2011) Cell substrates for the production of vaccines for human use. In: European Pharmacopoeia, 7th edn. Council of Europe, StrasbourgGoogle Scholar
  13. Cumming DA (1991) Glycosylation of recombinant protein therapeutics: Control and functional implications. Glycobiology 1:115–130CrossRefGoogle Scholar
  14. Dell A, Galadari A, Sastre F, Hitchen P (2011) Similarities and differences in the glycosylation mechanisms in prokaryotes and eukaryotes. Int J Microbiol 2010:148178PubMedCentralGoogle Scholar
  15. Dos Santos NV, De Carvalho Santos-Ebinuma V, Pessoa A Jr, Brandao Pereira JF (2018) Liquid-liquid extraction of biopharmaceuticals from fermented broth: trends and future prospects. J Chem Technol Biotechnol 93(7):1845–1863CrossRefGoogle Scholar
  16. Eibl R, Eibl D (eds) (2011) Single-use technology in biopharmaceuticalmanufacture. Wiley, HobokenGoogle Scholar
  17. EMA (2011) Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products (EMA/410/01 rev.3)Google Scholar
  18. Etzel MR, Arunkumar A (2017) Charged ultrafiltration and microfiltration membranes for antibody purification. In: Gottschalk U (ed) Process scale purification of antibodies. Wiley, Hoboken. Scholar
  19. European Agency for the Evaluation of Medicinal Products (EMA) (1996) Note for guidance for virus validation studies: design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95)Google Scholar
  20. FDA, Center for Biologics Evaluation and Research (1990) Cytokine and growth factor pre-pivotal trial information package with special emphasis on products identified for consideration under 21 CFR 312 Subpart E. FDA, BethesdaGoogle Scholar
  21. FDA, Office of Biologicals Research and Review (1993) Points to consider in the characterization of cell lines used to produce biologicals. FDA, Rockville PikeGoogle Scholar
  22. Fulton SP (1994) Large scale processing of macromolecules. Curr Opin Biotechnol 5:201–205CrossRefGoogle Scholar
  23. Goldstein A, Molina O (2016) Implementation strategies and challenges: single use technologies. PepTalk PresentationGoogle Scholar
  24. Gottschalk U (2006) The renaissance of protein purification. BioPharm Int 19:S8–S9Google Scholar
  25. Groves MJ (1988) Parenteral technology manual: an introduction to formulation and production aspects of parenteral products. Interpharm Press, Buffalo GroveGoogle Scholar
  26. Hodge G (2004) Disposable components enable a new approach to biopharmaceutical manufacturing. BioPharm Int 15:38–49Google Scholar
  27. Homma T, Fuji M, Mori J, Kawakami T, Kuroda K, Taniguchi M (1993) Production of cellobiose by enzymatic hydrolysis: removal of ß-glucosidase from cellulase by affinity precipitation using chitosan. Biotechnol Bioeng 41:405–410CrossRefGoogle Scholar
  28. Hossler P, Khattak SF, Li ZJ (2009) Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19:936–949CrossRefGoogle Scholar
  29. ICH (International Conference on Harmonization) Topic Q6B (1999a) Specifications: test procedures and acceptance criteria for biotechnology/biological products.Google Scholar
  30. ICH (International Conference on Harmonization) Topic Q5A (1999b) Viral safety evaluation of biotechnology products derived from cell lines of human or animal originGoogle Scholar
  31. ICH (International Conference on Harmonization) Topic Q8 (R2) (2009) Pharmaceutical development.Google Scholar
  32. ICH (International Conference on Harmonization) (2017) Guideline M7 on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic riskGoogle Scholar
  33. James AM (1992) Introduction fundamental techniques. In: James AM (ed) Analysis of amino acids and nucleic acids. Butterworth-Heinemann, Oxford, pp 1–28Google Scholar
  34. Jones N (2015) Single-Use Processing for Microbial Fermentations. BioProcess Int 13:56–62CrossRefGoogle Scholar
  35. Kelley B (2009) Industrialization of mAb production technology. MAbs 1:443–452CrossRefGoogle Scholar
  36. Klegerman ME, Groves MJ (1992) Pharmaceutical biotechnology. Interpharm Press, Buffalo GroveGoogle Scholar
  37. Krasnova L, Wong CH (2016) Understanding the chemistry and biology of glycosylation with glycan synthesis. Annu Rev Biochem 85:599–630CrossRefGoogle Scholar
  38. Larsen B, Hwang J (2010) Mycoplasma, ureaplasma, and adverse pregnancy outcomes: a fresh look. Infect Dis Obstet Gynecol 2010:1–7Google Scholar
  39. Löwer J (1990) Risk of tumor induction in vivo by residual cellular DNA: quantitative considerations. J Med Virol 31:50–53CrossRefGoogle Scholar
  40. Luitjens A, Lewis J, Pralong A (2012) Single-use biotechnologies and modular manufacturing environments invite paradigm shifts in bioprocess development and biopharmaceutical manufacturing. In: Subramanian G (ed) Biopharmaceutical production technology, vol 1&2. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, pp 817–857CrossRefGoogle Scholar
  41. Maerz H, Hahn SO, Maassen A, Meisel H, Roggenbuck D, Sato T, Tanzmann H, Emmrich F, Marx U (1996) Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration. Nat Biotechnol 14:651–652CrossRefGoogle Scholar
  42. Marcus-Sekura CJ (1991) Validation and removal of human retroviruses. Center for Biologics Evaluation and Research, FDA, BethesdaGoogle Scholar
  43. Minor PD (1994) Ensuring safety and consistency in cell culture production processes: viral screening and inactivation. Trends Biotechnol 12:257–261CrossRefGoogle Scholar
  44. Monteclaro F (2010) Protein expression systems, ringing in the new. Innov Pharm Technol 12:45–49Google Scholar
  45. Orzaez D, Granell A, Blazquez MA (2009) Manufacturing antibodies in the plant cell. Biotechnol J 4:1712–1724CrossRefGoogle Scholar
  46. PDA (2005) PDA technical report no. 41: virus filtration. PDA J Pharm Sci Technol 59(S-2):1–42Google Scholar
  47. Peters J, Stoger E (2011) Transgenic crops for the production of recombinant vaccines and anti-microbial antibodies. Hum Vaccin 7:367–374CrossRefGoogle Scholar
  48. Sharma SK (1990) Key issues in the purification and characterization of recombinant proteins for therapeutic use. Adv Drug Deliv Rev 4:87–111CrossRefGoogle Scholar
  49. Shukla AA, Thömmes J (2010) Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28:253–261CrossRefGoogle Scholar
  50. Shukla AA, Wolfe LS, Mostafa SS, Norman C (2017) Evolving trends in mAb production processes. Bioeng Transl Med 2:58–69CrossRefGoogle Scholar
  51. Sinclair A, Brower M, Lopes AG, Pollard D, Abe Y (2016) Standardized economic cost modeling for next-generation MAb production. BioProcess Int 14:14–23Google Scholar
  52. Sinclair AM, Elliott S (2005) Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 94:1626–1635CrossRefGoogle Scholar
  53. Tennikova T, Svec F (1993) High performance membrane chromatography: highly efficient separation method for proteins in ion-exchange, hydrophobic interaction and reversed phase modes. J Chromatogr 646:279–288CrossRefGoogle Scholar
  54. Terstappen G, Ramelmeier R, Kula M (1993) Protein partitioning in detergent-based aqueous two-phase systems. J Biotechnol 28:263–275CrossRefGoogle Scholar
  55. Turner R, Joseph A, Titchener-Hooker N, Bender J (2017) Manufacturing of proteins and antibodies: chapter downstream processing technologies, harvest operations. In: Advances biochemical engineering/biotechnology. Springer, BerlinGoogle Scholar
  56. Van Wezel AL, Van der Velden-de Groot CA, De Haan HH, Van den Heuvel N, Schasfoort R (1985) Large scale animal cell cultivation for production of cellular biologicals. Dev Biol Stand 60:229–236PubMedGoogle Scholar
  57. Walsh C (2006) Posttranslational modification of proteins: expanding nature’s inventory, vol xxi. Roberts and Co. Publishers, Englewood, p 490Google Scholar
  58. Walter J, Werner RG (1993) Regulatory requirements and economic aspects in downstream processing of biotechnically engineered proteins for parenteral application as pharmaceuticals. In: Kroner KH, Papamichael N, Schütte H (eds) Downstream processing, recovery and purification of proteins, a handbook of principles and practice. Carl Hauser Verlag, MuenchenGoogle Scholar
  59. Walter J, Werz W, McGoff P, Werner RG, Berthold W (1991) Virus removal/inactivation in downstream processing. In: Spier RE, Griffiths JB, MacDonald C (eds) Animal cell technology: development, processes and products. Butterworth-Heinemann Ltd. Linacre House, Oxford, pp 624–634Google Scholar
  60. Walter K, Werz W, Berthold W (1992) Virus removal and inactivation, concept and data for process validation of downstream processing. Biotech Forum Eur 9:560–564Google Scholar
  61. Wheelwright SM (1993) Designing downstream processing for large scale protein purification. Biotechnology 5:789–793Google Scholar
  62. WHO (World Health Organization) (2010) Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks. Technical report series, proposed replacement of 878, annex 1. WHO, GenevaGoogle Scholar
  63. Yao J, Weng Y, Dickey A, Tressel KY (2015) Plants as factories for human pharmaceuticals: applications and challenges. Int J Mol Sci 16:28549–28565CrossRefGoogle Scholar
  64. Zhou JX, Tressel T (2006) Basic concepts in Q membrane chromatography for large scale antibody production. Biotechnol Prog 22:341–349CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Batavia BiosciencesLeidenThe Netherlands
  2. 2.BiocerosUtrechtThe Netherlands

Personalised recommendations